Literature DB >> 24611073

Current state of medical thromboprophylaxis in Australia.

Sophie E Noel1, J Alasdair Millar1.   

Abstract

BACKGROUND: Australia has two published national guidelines for general medical thromboprophylaxis (MT), but the two differ in detail and the basis for patient selection remains uncertain. Several aspects of current guidelines are controversial, as is the proposed design of a dedicated prescribing box in the National Inpatient Medication Chart. AIM: To discuss and comment on the current standing of medical thromboprophylaxis in Australia.
METHOD: We have marshalled literature known to us from our previous published research, and have applied this knowledge to discuss shortcomings, which, in our opinion, exist in current medical thromboprophylaxis practice, and to suggest solutions.
CONCLUSION: Australian guidelines are flawed because they are based on unsuitable evidence (incidence of subclinical thrombotic disease) and define eligibility broadly, such that about 80 per cent of patients are considered eligible. They urge that prescribers should "consider" prophylaxis without supplying an adequate basis for doing so. They do not provide grounds for assessing the balance between hazard (in the form of major bleeds) and benefit (thrombotic events avoided). Other clinical factors promoting unnecessary use of medical thromboprophylaxis include the use of age as a risk factor and proposed inclusion of a new DVT prophylaxis section in the National Inpatient Medication Chart (NIMC), which implicitly discourages non-prescription of prophylaxis.

Entities:  

Keywords:  Thromboprophylaxis; guidelines; low molecular weight heparin; medical patients; risk factor analysis

Year:  2014        PMID: 24611073      PMCID: PMC3941577          DOI: 10.4066/AMJ.2014.1915

Source DB:  PubMed          Journal:  Australas Med J        ISSN: 1836-1935


  23 in total

1.  NICE's recommendations for thromboembolism are not evidence based.

Authors:  Mark Welfare
Journal:  BMJ       Date:  2011-12-07

2.  Time to reconsider NICE guidance on heparin prophylaxis in medical inpatients.

Authors:  Domnick Felix D'Costa
Journal:  BMJ       Date:  2011-12-06

3.  Genesis of medical thromboprophylaxis guidelines in Australia: a need for transparency and standardisation in guideline development.

Authors:  J Alasdair Millar
Journal:  Med J Aust       Date:  2009-04-20       Impact factor: 7.738

4.  Prophylaxis rates for venous thromboembolism and gastrointestinal bleeding in general medical patients: too low or too high?

Authors:  Shoshana J Herzig; Michael B Rothberg
Journal:  BMJ       Date:  2012-05-18

5.  Risk of venous thromboembolism among hospitalized medically ill patients.

Authors:  John Edelsberg; May Hagiwara; Charu Taneja; Gerry Oster
Journal:  Am J Health Syst Pharm       Date:  2006-10-15       Impact factor: 2.637

6.  A comparison of enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. Prophylaxis in Medical Patients with Enoxaparin Study Group.

Authors:  M M Samama; A T Cohen; J Y Darmon; L Desjardins; A Eldor; C Janbon; A Leizorovicz; H Nguyen; C G Olsson; A G Turpie; N Weisslinger
Journal:  N Engl J Med       Date:  1999-09-09       Impact factor: 91.245

7.  Increasing age is a major risk factor for hemorrhagic complications after pulmonary embolism thrombolysis.

Authors:  K M Mikkola; S R Patel; J A Parker; F Grodstein; S Z Goldhaber
Journal:  Am Heart J       Date:  1997-07       Impact factor: 4.749

8.  Selection of medical patients for prophylaxis of venous thromboembolism based on analysis of the benefit-hazard ratio.

Authors:  J A Millar
Journal:  Intern Med J       Date:  2009-09       Impact factor: 2.048

9.  Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  William H Geerts; David Bergqvist; Graham F Pineo; John A Heit; Charles M Samama; Michael R Lassen; Clifford W Colwell
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

10.  Development and validation of risk prediction algorithm (QThrombosis) to estimate future risk of venous thromboembolism: prospective cohort study.

Authors:  Julia Hippisley-Cox; Carol Coupland
Journal:  BMJ       Date:  2011-08-16
View more
  1 in total

1.  Real-World Data on Characteristics and Management of Community Patients Receiving Anticoagulation Therapy Who Presented with Acute Bleeding to the Emergency Department at a Regional Australian Hospital: A Prospective Observational Study.

Authors:  Fayez Hanna; Annemarie Hyppa; Ajay Prakash; Usira Vithanarachchi; Hizb U Dawar; Zar Sanga; George Olabode; Hamish Crisp; Alhossain A Khalafallah
Journal:  Mediterr J Hematol Infect Dis       Date:  2021-03-01       Impact factor: 2.576

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.